These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 28629844)

  • 1. Circulating tumor DNA: Solid data from liquid biopsies.
    Schrump DS
    J Thorac Cardiovasc Surg; 2017 Sep; 154(3):1132-1133. PubMed ID: 28629844
    [No Abstract]   [Full Text] [Related]  

  • 2. Liquid Biopsy Promotes Non-Small Cell Lung Cancer Precision Therapy.
    Lu J; Han B
    Technol Cancer Res Treat; 2018 Jan; 17():1533033818801809. PubMed ID: 30244652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer.
    Villaflor V; Won B; Nagy R; Banks K; Lanman RB; Talasaz A; Salgia R
    Oncotarget; 2016 Oct; 7(41):66880-66891. PubMed ID: 27602770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single tube liquid biopsy for advanced non-small cell lung cancer.
    de Wit S; Rossi E; Weber S; Tamminga M; Manicone M; Swennenhuis JF; Groothuis-Oudshoorn CGM; Vidotto R; Facchinetti A; Zeune LL; Schuuring E; Zamarchi R; Hiltermann TJN; Speicher MR; Heitzer E; Terstappen LWMM; Groen HJM
    Int J Cancer; 2019 Jun; 144(12):3127-3137. PubMed ID: 30536653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liquid Biopsy and Lung Cancer.
    Pisapia P; Malapelle U; Troncone G
    Acta Cytol; 2019; 63(6):489-496. PubMed ID: 30566947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Features of Patients with an Epidermal Growth Factor Receptor T790M Mutation Detected in Circulating Tumor DNA.
    Ikushima H; Sakatani T; Usui K
    Oncology; 2020; 98(1):23-28. PubMed ID: 31494653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection and Monitoring of the BRAF Mutation in Circulating Tumor Cells and Circulating Tumor DNA in BRAF-Mutated Lung Adenocarcinoma.
    Guibert N; Pradines A; Casanova A; Farella M; Keller L; Soria JC; Favre G; Mazières J
    J Thorac Oncol; 2016 Sep; 11(9):e109-12. PubMed ID: 27165943
    [No Abstract]   [Full Text] [Related]  

  • 8. Will liquid biopsies become our fluid transition to personalized immunotherapy?
    Wauters E; Vansteenkiste J
    Ann Oncol; 2018 Jan; 29(1):11-13. PubMed ID: 29165546
    [No Abstract]   [Full Text] [Related]  

  • 9. Analysis of circulating tumor DNA: The next paradigm shift in detection and treatment of lung cancer.
    Schrump DS; Hong JA
    J Thorac Cardiovasc Surg; 2018 Jun; 155(6):2632-2633. PubMed ID: 29776293
    [No Abstract]   [Full Text] [Related]  

  • 10. Circulating cell-free DNA and circulating tumor cells, the "liquid biopsies" in ovarian cancer.
    Cheng X; Zhang L; Chen Y; Qing C
    J Ovarian Res; 2017 Nov; 10(1):75. PubMed ID: 29132396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liquid biopsy in 2016: Circulating tumour cells and cell-free DNA in gastrointestinal cancer.
    Pantel K; Alix-Panabières C
    Nat Rev Gastroenterol Hepatol; 2017 Feb; 14(2):73-74. PubMed ID: 28096542
    [No Abstract]   [Full Text] [Related]  

  • 12. [Research progress of circulating tumor DNA methylation in non-small cell lung cancer].
    Yang Lan L; Chen Bojiang BJ; Li Lei L
    Zhonghua Jie He He Hu Xi Za Zhi; 2018 Dec; 41(12):967-970. PubMed ID: 30522195
    [No Abstract]   [Full Text] [Related]  

  • 13. Potential of circulating biomarkers in liquid biopsy diagnostics.
    Yeo JC; Lim CT
    Biotechniques; 2018 Oct; 65(4):187-189. PubMed ID: 30284936
    [No Abstract]   [Full Text] [Related]  

  • 14. Role of liquid biopsies in colorectal cancer.
    Wills B; Gorse E; Lee V
    Curr Probl Cancer; 2018 Nov; 42(6):593-600. PubMed ID: 30268335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cell-free tumour DNA as a diagnostic and prognostic biomarker in non-small cell lung carcinoma.
    Łochowska BA; Nowak D; Białasiewicz P
    Adv Respir Med; 2019; 87(2):118-122. PubMed ID: 31038724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urine circulating-tumor DNA (ctDNA) detection of acquired EGFR T790M mutation in non-small-cell lung cancer: An outcomes and total cost-of-care analysis.
    Sands J; Li Q; Hornberger J
    Lung Cancer; 2017 Aug; 110():19-25. PubMed ID: 28676213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heterogeneous mutation pattern in tumor tissue and circulating tumor DNA warrants parallel NGS panel testing.
    Guo Q; Wang J; Xiao J; Wang L; Hu X; Yu W; Song G; Lou J; Chen J
    Mol Cancer; 2018 Aug; 17(1):131. PubMed ID: 30153823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Applications of liquid biopsies for cancer.
    Mattox AK; Bettegowda C; Zhou S; Papadopoulos N; Kinzler KW; Vogelstein B
    Sci Transl Med; 2019 Aug; 11(507):. PubMed ID: 31462507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Possible applications of circulating tumor cells in patients with non small cell lung cancer.
    Tartarone A; Rossi E; Lerose R; Mambella G; Calderone G; Zamarchi R; Aieta M
    Lung Cancer; 2017 May; 107():59-64. PubMed ID: 27339469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating tumor DNA for personalized lung cancer monitoring.
    Fiala C; Diamandis EP
    BMC Med; 2017 Aug; 15(1):157. PubMed ID: 28814291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.